Prime Medicine, Inc. (PRME) Stock Score, Valuation & Financial Research

Prime Medicine, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PRME

Prime Medicine, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.13. These figures are a research snapshot, not a buy or sell recommendation.

What Prime Medicine, Inc. does

Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Prime Medicine is a biotechnology company that generates revenue primarily through research collaboration agreements with pharmaceutical partners. The company is currently in the development stage and does not have any approved commercial products, meaning it relies on upfront payments, milestone payments, and research funding from these collaborations to support its operations.

Products and services

  • The company is developing a portfolio of one-time curative genetic therapies using its proprietary Prime Editing platform, which is designed to precisely edit genes to treat various diseases in hematology, immunology, oncology, liver, and lung areas.

Annual revenue by business

  • Reportable Segment: USD 4,632,000 · 100.00% calculated revenue share (period 2025-12-31) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Bristol Myers Squibb — A strategic collaboration and license agreement focused on the development of ex vivo T-cell therapies. Source

Competitors and product-market comparisons

  • CRISPR Therapeutics — Competes in the development of gene editing therapies using CRISPR/Cas9 technology. Source
  • Editas Medicine — Competes in the development of gene editing therapies. Source
  • Intellia Therapeutics — Competes in the development of gene editing therapies. Source

Business strengths to evaluate

  • Proprietary Prime Editing platform technology Source
  • Diversified pipeline of therapeutic programs Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and collaborators Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source · Reportable Segment

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PRME financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.13
Market capitalization:
567.71M (currency not supplied)
Revenue:
USD 4.07M
Net income:
USD -187.89M
Free cash flow:
USD -167.1M
Cash:
USD 47.45M
Total debt:
USD 112.48M
EPS:
USD -1.10

What stands out

  • Reported year-over-year revenue growth is -12.1%.
  • Free cash flow is USD -167.1M, negative for the stored period.
  • The balance sheet shows USD 47.45M of cash versus USD 112.48M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -4102.5% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -4613.1% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Debt exceeds cash by USD 65.03M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PRME

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • What is driving PRME's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
  • How long can PRME fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is PRME's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for PRME to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of PRME's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research PRME

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.